Also found in: Medical, Wikipedia.
Related to pramlintide: Colesevelam, Exenatide, Symlin


An injectable drug that is a synthetic analog of the hormone amylin, used in the form of its acetate salt to treat type 1 and type 2 diabetes.

[pram-, of unknown origin + -lintide, amylin derivative or mimic suffix ((amy)lin + (pep)tide).]
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.


n pramlintida
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
References in periodicals archive ?
This industry includes establishments that produce drugs such as insulin, pramlintide and other drugs to treat diabetes, anti-thyroid drugs to treat hyperthyroidism, and other drugs to treat pituitary gland, adrenal gland and parathyroid gland disorders.
Pramlintide (Symlin; AstraZeneca, Cambridge, United Kingdom), a synthetic amylin analog, lowers the glycated hemoglobin (HbA1c) level in patients with type 1 and 2 diabetes, slows down gastric emptying, reduces appetite, and exerts favorable effects on body weight.
Other medications, such as metformin and pramlintide, might also be prescribed.
The injectable, pramlintide, is currently the only amylin analog available.
(4) Pramlintide is a synthetic amylin used to manage both T1 and T2DM by reducing insulin requirements.
Hwang et al., "Neuroprotective effects of the amylin analogue pramlintide on Alzheimer's disease pathogenesis and cognition," Neurobiology of Aging, vol.
The medication, pramlintide (Symlin), slows the absorption of food and may cause some weight loss, according to the ADA.
However, because of its amyloidogenic potential, its analog pramlintide has been approved by the FDA, for use in DM type 1 and type 2.
Pramlintide (FDA 2005) is an incretin cosecreted with insulin, which suppresses glucagon and delays gastric emptying [8].
Keywords: Alpha-glucosidase inhibitors, DPP4 inhibitors, GLP1 receptor agonists, Metformin, Pioglitazone, Pramlintide, SGLT2 inhibitors.
IAPP hyposecretion is well-established in T1DM and insulin-requiring T2DM [43,45]: A synthetic IAPP, pramlintide [28-30] (pro-hIAPP) has been used for treating both T1DM and insulin-requiring T2DM together with insulin replacement for a better glycemic control [46-49].
The effect of pramlintide acetate on glycemic control and weight in patients with type 2 diabetes mellitus and in obese patients without diabetes: a systematic review and meta-analysis.